interaction records 54 assistance programs 55 0 personal data stored
OmniRx › Tools › Generic competition check › Clobazam

Generic competition · all medicines · read 12 November 2026

Is there a generic of Clobazam, and who makes it?

Clobazam appears in 3 dosage-form groups in the FDA Orange Book as of 12 November 2026, with 13 generic makers listed as marketed across them. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming. Where both are dated, the first generic approval came between 5.9 and 7 years after the first brand approval. This is the Orange Book's listing, not a forecast.

Compiled and checked by Vincent Wesley Couey (ORCID 0009-0005-6869-308X) from the Orange Book data files, downloaded 12 November 2026.

Not medical advice. This page reports what the FDA's Orange Book lists, not what a pharmacy has in stock, what anything costs, or whether a generic is right for you. Ask your pharmacist or prescriber about your own medicine.
Clobazam3 dosage-form groups in the Orange Book
13generic makers listed
  1. Clobazam appears in 3 dosage-form groups in the FDA Orange Book as of 12 November 2026, with 13 generic makers listed as marketed across them.
  2. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming.
  3. Where both are dated, the first generic approval came between 5.9 and 7 years after the first brand approval.
  4. Patents and exclusivities are shown as listed by the application holder; the Orange Book does not rule on them, and a listed patent is not a statement that a generic is blocked. This says nothing about price, supply or quality.

Tablet, Oral

Four or more generic makers listed

Brand listed as marketed: Onfi. 10 generic makers with 21 generic products listed as marketed; the first generic approval is dated 22 October 2018.

20102015202020252030010brand 2011Amneal Pharmaceuticals Co Gmbh, first approval 22 October 2018Bionpharma Inc, first approval 22 October 2018Hetero Labs Ltd Unit Iii, first approval 22 October 2018Pharmazone, first approval 22 October 2018Upsher Smith Laboratories Llc, first approval 22 October 2018Zydus Pharmaceuticals Usa Inc, first approval 22 October 2018Lupin Ltd, first approval 14 December 2018Micro Labs Ltd, first approval 30 January 2019Alkem Laboratories Ltd, first approval 6 September 2019Msn Laboratories Private Ltd, first approval 11 May 2021data date
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end
Generic maker (applicant)First approvalProducts
Amneal Pharmaceuticals Co Gmbh22 October 20182
Bionpharma Inc22 October 20182
Hetero Labs Ltd Unit Iii22 October 20182
Pharmazone22 October 20182
Upsher Smith Laboratories Llc22 October 20182
Zydus Pharmaceuticals Usa Inc22 October 20182
Lupin Ltd14 December 20182
Micro Labs Ltd30 January 20192
Alkem Laboratories Ltd6 September 20193
Msn Laboratories Private Ltd11 May 20212

Patents and exclusivities still listed

No unexpired patent or exclusivity is listed against the marketed brand products in this group.

Suspension, Oral

Four or more generic makers listed

Brand listed as marketed: Onfi. 7 generic makers with 7 generic products listed as marketed; the first generic approval is dated 22 October 2018.

2010201520202025203007brand 2012Amneal Pharmaceuticals Llc, first approval 22 October 2018Bionpharma Inc, first approval 22 October 2018Taro Pharmaceutical Industries Ltd, first approval 15 April 2019Hetero Labs Ltd Unit Iii, first approval 24 February 2020Chartwell Molecular Holdings Llc, first approval 24 April 2020Alkem Laboratories Ltd, first approval 6 May 2021Aurobindo Pharma Ltd, first approval 24 March 2022data date
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end
Generic maker (applicant)First approvalProducts
Amneal Pharmaceuticals Llc22 October 20181
Bionpharma Inc22 October 20181
Taro Pharmaceutical Industries Ltd15 April 20191
Hetero Labs Ltd Unit Iii24 February 20201
Chartwell Molecular Holdings Llc24 April 20201
Alkem Laboratories Ltd6 May 20211
Aurobindo Pharma Ltd24 March 20221

Patents and exclusivities still listed

No unexpired patent or exclusivity is listed against the marketed brand products in this group.

Film, Oral

Brand listed, no generic listed as marketed

Brand listed as marketed: Sympazan. No generic is listed as marketed.

20152020202520302035204001brand 2018data datePatent 12403090 listed to expire 5 September 2039Patent 12290597 listed to expire 5 September 2039Patent 11541002 listed to expire 31 January 2040
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end

Patents and exclusivities still listed

  • 5 September 2039Patent 12403090 drug product
  • 5 September 2039Patent 12290597 drug product
  • 31 January 2040Patent 11541002 drug product

US Food and Drug Administration, Orange Book data files, downloaded 12 November 2026. A listed patent is not a ruling that a generic is blocked, and no figure here says anything about price, supply or quality. Check the Orange Book.

Where can you go from this result?

Open it in the check to search another medicine, or see every brand with no generic listed. The FDA explains generic approval in how generic drugs are approved and the FDA generic drug facts, and the Orange Book itself is the FDA Orange Book. To check what is available now, ask your pharmacist, and see the FDA drug shortages page.